Consolidated profit before tax (PBT) rose 45.53% to Rs 15.47 crore in Q3 FY22 from Rs 10.63 crore in Q3 FY21.
On a standalone basis, Vimta Labs' net profit surged 44.31% to Rs 11.56 crore on a 14.60% increase in revenue from operations to Rs 66.68 crore in Q3 FY22 over Q3 FY21.
Vimta Labs provides services of testing and contract research in the fields of clinical and pre-clinical studies, clinical reference, analytical testing, advanced molecular biology and environmental studies. It supports regulatory authorities in mandatory certification of food and agricultural products exported from India.
Shares of Vimta Labs lost 0.59% to Rs 427.30 on BSE.
Powered by Capital Market - Live News
FOR GRIEVANCE MAIL TO invgrieviss@iseindia.com
BSE EQUITIES : INB011077733 | NSE F&O EQUITIES : INF231077737 | NSE CASH MARKET : INB231077737 | NSE CURRENCY DERIVATIVES : INE231077737 | MCX-SX : INE261077737
ISS Enterprise Limited [Erstwhile: ISE Securities & Services Limited], a wholly owned subsidiary of Inter-connected Stock Exchange of India Ltd. (ISE)
© 2013 ISS Enterprise Limited [Erstwhile: ISE Securities & Services Limited]. All rights reserved.
Designed, developed & powered by C-MOTS Infotech (ISO 9001:2008 certified)